pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges (nicotinell？)药物动力学、安全性和疗效的随机对照试验1和2毫克尼古丁酒石酸氢盐糖锭(nicotinell ).pdfVIP

下载本文档

7
0
约9.54万字
约 15页
2017-09-11 发布于上海
举报
版权申诉

pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges (nicotinell？)药物动力学、安全性和疗效的随机对照试验1和2毫克尼古丁酒石酸氢盐糖锭(nicotinell ).pdf

1、本文档共15页，可阅读全部内容。
2、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
5、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
6、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
7、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
8、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges (nicotinell？)药物动力学、安全性和疗效的随机对照试验1和2毫克尼古丁酒石酸氢盐糖锭(nicotinell )

BMC Clinical Pharmacology BioMed Central Research article Open Access Pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges (Nicotinell®) 1 2 3 Bertrand Dautzenberg , Mitchell Nides , Jean-Luc Kienzler and Anne Callens*4 Address: 1Groupe Hospitalier Pitié-Salpêtrière, Paris, France, 2Los Angeles Clinical Trials, Los Angeles, CA, USA, 3Novartis Consumer Health S.A., Nyon, Switzerland and 4Novartis Santé Familiale, Rueil-Malmaison, France Email: Bertrand Dautzenberg - bertrand.dautzenberg@psl.aphp.fr; Mitchell Nides - mnides@; Jean-Luc Kienzler - jean- luc.kienzler@; Anne Callens* - anne.callens@ * Corresponding author Published: 8 October 2007 Received: 7 December 2006 Accepted: 8 October 2007 BMC Clinical Pharmacology 2007, 7:11 doi:10.1186/1472-6904-7-11 This article is available from: /1472-6904/7/11 © 2007 Dautzenberg et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: The use of nicotine replacement therapy (NRT) can almost double the chances of success for smokers to quit. Nevertheless, there is still a considerable number of cessation attempts that are made without any treatment. This novel oral formulation, (lozenge containing nicotine bitartrate dihydrate) has been develop